Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis

Biomarkers in Medicine

Volumn 9, Issue 12, 2015, Pages 1343-1351

  Conti, Fabio ^a   Dall'Agata, Marco ^b   Gramenzi, Annagiulia ^a   Biselli, Maurizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

biomarkers; cirrhosis; hepatocellular carcinoma; infection; liver; surveillance

Indexed keywords

AGGLUTININ; ALPHA FETOPROTEIN; ALPHA LEVO FUCOSIDASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DECARBOXYPROTHROMBIN; GLYPICAN 3; PROCALCITONIN;

BACTERIAL INFECTION; BACTERIUM IDENTIFICATION; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BACTERIAL INFECTIONS; CARCINOMA, HEPATOCELLULAR; COMPLICATION; LIVER NEOPLASMS; METABOLISM;

BACTERIAL INFECTIONS; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; EARLY DIAGNOSIS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 84948683910     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.100     Document Type: Review

References (75)

1. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 50, 2022-2033 (2009).
2. Fernandez J, Gustot T. Management of bacterial infection in cirrhosis. J. Hepatol. 56, S1-S12 (2012).
3. Arvaniti V, D'Amico G, Fede G et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 139, 1246-1256 (2010).
4. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: Analysis of the National Hospital Discharge Survey. Chest 124, 1016-1020 (2003).
5. Fernandez J, Navasa M, Gomez J et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 35, 140-148 (2002).
6. Fernández J, Acevedo J, Castro M et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study. Hepatology 55, 1551-1561 (2012).
7. Forner A, Llover JM, Bruix J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012).
8. Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 29, 1299-1305 (2008).
9. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 127, S35-S50 (2004).
10. Stravitz RT, Heuman DM, Chand N et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am. J. Med. 121, 119-126 (2008).
11. Santi V, Trevisani F, Gramenzi A et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J. Hepatol. 53, 291-297 (2010).
12. Singal A, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment. Pharmacol. Ther. 30, 37-47 (2009).
13. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med. 41, 580-637 (2013).
14. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J. Hepatol. 51, 475-482 (2009).
15. Abdel-Khalek EE, El-Fakhry A, Helaly M, Hamed M, Elbaz O. Systemic inflammatory response syndrome in patients with liver cirrhosis. Arab. J. Gastroenterol. 12, 173-177 (2011).
16. Behroozian R, Bayazidchi M, Rasooli J. Systemic inflammatory response syndrome and MELD score in hospital outcome of patients with liver cirrhosis. Middle East J. Dig. Dis. 4, 168-172 (2012).
17. Papp M, Vitalis Z, Altorjay I et al. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. Liver Int. 32, 603-611 (2012).
18. Li CH, Yang RB, Pang JH et al. Procalcitonin as a biomarker for bacterial infections in patients with liver cirrhosis in the emergency department. Acad. Emerg. Med. 18, 121-126 (2011).
19. Bota DP, Van Nuffelen M, Zakariah AN, Vincent JL. Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J. Lab. Clin. Med. 146, 347-351 (2005).
20. Lazzarotto C, Ronsoni MF, Fayad L et al. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann. Hepatol. 12, 599-607 (2013).
21. Cervoni JP, Thévenot T, Weil D et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J. Hepatol. 56, 1299-1304 (2012).
22. Di Martino V, Coutris C, Cervoni JP et al. Prognostic value of C-reactive protein levels in patients with cirrhosis. Liver Transpl. 21(6), 753-760 (2015).
23. Marciano S, Haddad L, Martínez AP et al. Ultra-sensitive procalcitonin may help rule out bacterial infections in patients with cirrhosis. Ann. Hepatol. 13, 541-547 (2014).
24. Cekin Y, Cekin AH, Duman A, Yilmaz U, Yesil B, Yolcular BO. The role of serum procalcitonin levels in predicting ascitic fluid infection in hospitalized cirrhotic and noncirrhotic patients. Int. J. Med. Sci. 10, 1367-1374 (2013).
25. Al-Dorzi HM, Rishu AH, Tamim HM et al. Serum procalcitonin in cirrhotic patients with septic shock: relationship with adrenal insufficiency and clinical outcomes. Clin. Lab. 60, 1105-1114 (2014).
26. Mendall MA, Strachan DP, Butland BK et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur. Heart. J. 21, 1584-1590 (2000).
27. Hirschfield GM, Pepys M. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJ Med. 96, 793-807 (2003).
28. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin. Infect. Dis. 52, S346 (2011).
29. Le Moine O, Deviére J, Devaster JM et al. Interleukin-6: An early marker of bacterial infection in decompensated cirrhosis. J. Hepatol. 20, 819-824 (1994).
30. Albillos A, de-la-Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet; 363, 1608-1610 (2004).
31. Eto T, Kato J, Kitamura K. Regulation of production and secretion of adrenomedullin in the cardiovascular system. Regul. Pept. 112, 61-69 (2003).
32. Reuken PA, Kiehntopf M, Stallmach A, Bruns T. Midregional pro-adrenomedullin (MR-proADM): An even better prognostic biomarker than C reactive protein to predict short-term survival in patients with decompensated cirrhosis at risk of infection J. Hepatol. 57, 1156-1158 (2012).
33. Nahm CH, Choi JW, Lee J. Delta neutrophil index in automated immature granulocyte counts for assessing disease severity of patients with sepsis. Ann. Clin. Lab. Sci. 38, 241-246 (2008).
34. Lim TS, Kim BK, Lee JW et al. Use of the delta neutrophil index as a prognostic factor of mortality in patients with spontaneous bacterial peritonitis: Implications of a simple and useful marker. PLoS ONE 9, e86884 (2014).
35. Hardick J, Won H, Jeng K et al. Identification of bacterial pathogens in ascitic fluids from patients with suspected spontaneous bacterial peritonitis by use of broad-range PCR [16S PCR] coupled with high-resolution melt analysis. J. Clin. Microbiol. 50, 2428-2432 (2012).
36. Gupta S, Bent S, Kohlwes J. Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann. Intern. Med. 139, 46-50 (2003).
37. Colli A, Fraquelli M, Casazza G et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: A systematic review. Am. J. Gastroenterol. 101, 513-523 (2011).
38. Lok AS, Sterling RK, Everhart JE et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138, 493-502 (2010).
39. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alphafetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127, S108-S112 (2004).
40. Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137, 110-118 (2009).
41. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 53, 1020-1022 (2011).
42. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012).
43. Poon D, Anderson BO, Chen LT et al. Asian Oncology Summit. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 10, 1111-1118 (2009).
44. Lee E, Edward S, Singal AG, Lavieri MS, Volk M. Improving screening for hepatocellular carcinoma by incorporating data on levels of-fetoprotein, over time. Clin. Gastroenterol. Hepatol. 11, 437-440 (2013).
45. Biselli M, Conti F, Gramenzi A et al. A new approach to the use of-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. Br. J. Cancer 112, 69-76 (2015).
46. El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 146, 1249-1255 (2014).
47. Shao Y-Y, Hsu C-H, Cheng A-L. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer 2, 93-107 (2013).
48. Hayashi K, Kumada T, Nakano S et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am. J. Gastroenterol. 94, 3028-3033 (1999).
49. Okuda K, Tanaka M, Kanazawa N et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutininreactive alpha-fetoprotein. Int. J. Oncol. 14, 265-271 (1999).
50. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig. Dis. Sci. 55, 2744-2755 (2010).
51. Song BC, Suh DJ, Yang SH et al. Lens culinaris agglutininreactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. J. Clin. Gastroenterol. 35, 398-402 (2002).
52. Taketa K, Sekiya C, Namiki M et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 99, 508-518 (1990).
53. Oka H, Saito A, Ito K et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alphafetoprotein. J. Gastroenterol. Hepatol. 16, 1378-1383 (2001).
54. Yamagata Y, Katoh H, Nakamura K, Tanaka T, Satomura S, Matsuura S. Determination of alpha-fetoprotein concentration based on liquid-phase binding assay using anion exchange chromatography and sulfated peptide introduced antibody. J. Immunol. Methods 212, 161-168 (1998).
55. Kagebayashi C, Yamaguchi I, Akinaga A et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal. Biochem. 388, 306-311 (2009).
56. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig. Dis. Sci. 55, 3576-3583 (2010).
57. Hanaoka T, Sato S, Tobita H et al. Clinical significance of the highly sensitive fucosylated fraction of-fetoprotein in patients with chronic liver disease. J. Gastroenterol. Hepatol. 26, 739-744 (2011).
58. Toyoda H, Kumada T, Tada T et al. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/ml. Cancer Sci. 102, 1025-1031 (2011).
59. Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive-fetoprotein and des-carboxy prothrombin in histologically prove hepatocellular carcinoma in the United States. Dig. Dis. Sci. 52, 776-782 (2007).
60. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: A comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 3, 79-87 (2007).
61. Marrero JA, Su GL, Wei W et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 37, 1114-1121 (2003).
62. Nakamura S, Nouso K, Sakaguchi K et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am. J. Gastroenterol. 101, 2038-2043 (2006).
63. Baek YH, Lee JH, Jang JS et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology 56, 763-767 (2009).
64. Uehara S, Gotoh K, Handa H, Tomita H, Senshuu M. Distribution of the heterogeneity of des-gammacarboxyprothrombin in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 20, 1545-1552 (2005).
65. Filmus J, Selleck SB. Glypicans: Proteoglycans with a surprise. J. Clin. Invest. 108, 497-501 (2001).
66. Zhu ZW, Friess H, Wang L et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48, 558-564 (2001).
67. Xu C, Yan Z, Zhou L, Wang Y. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: A meta-analysis. J. Cancer Res. Clin. Oncol. 139, 1417-1424 (2013).
68. Fawzy Montaser M, Amin Sakr M, Omar Khalifa M. Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma. Arab. J. Gastroenterol. 13, 9-13 (2012).
69. Pillai AA, Fimmel CJ. Emerging serum biomarkers of HCC. Clin. Gastroenterol. 27, 247-262 (2012).
70. Tangkijvanich P, Tosukhowong P, Bunyongyod P et al. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J. Trop. Med. Public Health. 30(1), 110-114 (1999).
71. Wright LM, Kreikemeier JT, Fimmel CJ. A concise review of serum markers for hepatocellular cancer. Cancer Detect. Prev. 31, 35-44 (2007).
72. Sterling RK, Jeffers L, Gordon F et al. Utility of Lens culinaris agglutinin-reactive fraction of alphafetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 7, 104-113 (2009).
73. Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol. Res. 44, E11-E25 (2014).
74. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10, 704-714 (2009).
75. Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: A potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig. Dis. Sci. 57, 2910-2916 (2012).